ProfileGDS5678 / 1447506_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 66% 66% 61% 66% 68% 66% 66% 66% 66% 66% 66% 66% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0053866
GSM967853U87-EV human glioblastoma xenograft - Control 24.005166
GSM967854U87-EV human glioblastoma xenograft - Control 33.9878466
GSM967855U87-EV human glioblastoma xenograft - Control 43.6330261
GSM967856U87-EV human glioblastoma xenograft - Control 53.9570266
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1535168
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0561166
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9878566
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9888366
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.998266
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9894766
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9919166
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0031266
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0060966